PTC/SB/08a (08-03)
Approved for use through 97/31/2006, ONE 0651-0201
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unfers it contains a valid OMS control number.

Remove

	Application Number	
	Filing Date	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Rami EVRON
(Not for submission under 37 CFR 1.99)	Art Unit	
(Not for Submission under St. St. 1.30)	Examiner Name	
	Attorney Docket Number	PHUS030466US2

U.S.PATENTS

	U.S.PATENTS			Wellieve					
Examiner Cite Initial* No Patent Number Kind Code		Issue Date Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear					
	1	5949811		1999-09-07	Baba, et al.		all		
	2	6385280	B1	2002-05-07	Bitti, et al.		all		
If you wis	h to a	dd additional U.S. Pate	ent citatio	n information p	olease click the	Add button.	_	Add	
			U.S.P	ATENT APPL	ICATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number		Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	20050031080	A1	2005-02-10	Klingenbeck	Regen, et al.	all		
If you wis	h to a	dd additional U.S. Pub	lished Ac	polication citati	on information	please click the Ad	ld buttor	Add	
				FOREIGN PA	TENT DOCU	MENTS		Remove	_
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²		Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1	WO 03/022018	wo	A1	2003-03-13	Siemens		all	
	2	EP 1 354 554	EP	A2	2003-10-22	GE Medical System	ms	all	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		
First Named Inventor Ram		EVRON
Art Unit		
Examiner Name		
Attorney Docket Numb	er	PHUS030466US2

		NON-PATENT LITERATURE DOCUMENTS Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publishere.	Τs
	1	COPPENRATH, E., et al.; Spiral CT of the abdomen: weight-adjusted dose reduction; 2001; Fortschr Rontgenstr, 173-52-56.	Z
	2	HONG, C., et al.; Coronary Artery Calcium Measurement with Mutil-Detector Row CT: In Vitro Assessment of Effect of Radiation Dose; 2002; Radiology; 225(3)801-906.	
	3	JUNG, B., et al.; Individually weight-adapted examination protocol in retrospectively EOG-gated MSCT of the heart; 2000; Eur Radiot; 13:2560-2566.	
	4	MAHNKEN, A.H., et al.; Detection of Colorsary Calcifications: Feasibility of Dose Reduction with a Body Weight- Adapted Examination Protocot, 2003, AJR, 181:533-538.	
	5	SEVRUKOV, A., et al.; Electron Beam Tomography Imaging of Coronary Calcium: The Effect of Body Mass Index on Radiologic Noise; 2002; J. Comp. Assist. Tomog.; 26(4):592-597.	
	6	STARCK, G, et al.: A method to obtain the same levels of CT image noise for patients of various sizes, to minimize radiation dose; 2002; B. J. of Radiology, 75:140-150.	
	7	TACK, D., et al.; Dose Reduction in Multidelector CT Using Attenuation-Based Online Tube Current Modulation; 2003, AJR, 191:331-334.	
	8	WILDBERGER, J.E., et al.: Individually Adapted Examination Protocols for Reduction of Radiation Exposure in Chest CT; 2001; Investigative Radiology; 36(10)604-611.	
If you wish	n to ac	dd additional non-patent literature document citation information please click the Add button Add	_

	Application Number		
NEODWATION DIGGI COURT	Filing Date		
NFORMATION DISCLOSURE	First Named Inventor	Ram	EVRON
STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Art Unit		
,	Examiner Name		
	Attorney Docket Numb	er	PHUS030466US2

EXAMINER SIGNATURE						
Examiner Signature		Date Considered				
*EXAMINER: Initial if	reference considered, whether or not citation is in conforma	ince with MPEP 609	Draw line through a			

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sec Not Octor of USPTO Pates Decorrect at year USPTO_GOV or MEDF 9016. If Set of other had search to document by the broadestor code (NIPO) Societied \$7.3, If you desprease patent octorwells, the exclusion of the year of the reign of the Emperor most precise the sental number of the patent document.

* Not of document by the appropriate symbols as exclusion on the document undow WHO Standard 51-16 position. * Applicated to produce a code on most of the sental number of the patent of the

Application Number Fling Date Fling Date Fling Date Fling Date Fling Date Fling Manuel Inventor Rami EVRON Art Unit Examiner Name Attorney Docket Number | PHIJS009468US2

CERTIFICATION STATEMENT

Please see	37 CFR	1 97 ar	nd 1 98 to	make the	appropriate	selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eVI).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- .7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/TML/	Date (YYYY-MM-DD)	2006-05-22
Name/Print	Thomas M. Lundin	Registration Number	48979

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.